Genome-wide germline correlates of the epigenetic landscape of prostate cancer.

Autor: Houlahan KE; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.; Vector Institute, Toronto, Ontario, Canada., Shiah YJ; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Gusev A; Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Yuan J; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA., Ahmed M; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Shetty A; Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; University of Cambridge, Cambridge, UK., Ramanand SG; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA., Yao CQ; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Bell C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., O'Connor E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Huang V; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Fraser M; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Heisler LE; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Livingstone J; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Yamaguchi TN; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Rouette A; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Foucal A; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Espiritu SMG; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Sinha A; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Sam M; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Timms L; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Johns J; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Wong A; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Murison A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Orain M; Department of Pathology, Centre de recheche du CHU de Québec-Université Laval, Québec City, Québec, Canada., Picard V; Division of Urology, Centre de recheche du CHU de Québec-Université Laval, Québec City, Québec, Canada., Hovington H; Division of Urology, Centre de recheche du CHU de Québec-Université Laval, Québec City, Québec, Canada., Bergeron A; Division of Urology, Centre de recheche du CHU de Québec-Université Laval, Québec City, Québec, Canada., Lacombe L; Division of Urology, Centre de recheche du CHU de Québec-Université Laval, Québec City, Québec, Canada., Lupien M; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Fradet Y; Division of Urology, Centre de recheche du CHU de Québec-Université Laval, Québec City, Québec, Canada., Têtu B; Department of Pathology, Centre de recheche du CHU de Québec-Université Laval, Québec City, Québec, Canada., McPherson JD; Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Pasaniuc B; Department of Computational Medicine, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, USA.; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA., Kislinger T; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Chua MLK; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., van der Kwast T; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Mani RS; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA., He HH; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Bristow RG; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. robert.bristow@manchester.ac.uk.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. robert.bristow@manchester.ac.uk.; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. robert.bristow@manchester.ac.uk.; Division of Cancer Sciences, Faculty of Biology, Health and Medicine, University of Manchester, Manchester, UK. robert.bristow@manchester.ac.uk.; The Christie NHS Foundation Trust, Manchester, UK. robert.bristow@manchester.ac.uk.; Cancer Research UK Manchester Institute, Manchester, UK. robert.bristow@manchester.ac.uk.; Manchester Cancer Research Centre, Manchester, UK. robert.bristow@manchester.ac.uk., Boutros PC; Ontario Institute for Cancer Research, Toronto, Ontario, Canada. pboutros@mednet.ucla.edu.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. pboutros@mednet.ucla.edu.; Vector Institute, Toronto, Ontario, Canada. pboutros@mednet.ucla.edu.; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA. pboutros@mednet.ucla.edu.; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. pboutros@mednet.ucla.edu.; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. pboutros@mednet.ucla.edu.; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. pboutros@mednet.ucla.edu.; Institute for Precision Health, University of California, Los Angeles, Los Angeles, CA, USA. pboutros@mednet.ucla.edu.
Jazyk: angličtina
Zdroj: Nature medicine [Nat Med] 2019 Oct; Vol. 25 (10), pp. 1615-1626. Date of Electronic Publication: 2019 Oct 07.
DOI: 10.1038/s41591-019-0579-z
Abstrakt: Oncogenesis is driven by germline, environmental and stochastic factors. It is unknown how these interact to produce the molecular phenotypes of tumors. We therefore quantified the influence of germline polymorphisms on the somatic epigenome of 589 localized prostate tumors. Predisposition risk loci influence a tumor's epigenome, uncovering a mechanism for cancer susceptibility. We identified and validated 1,178 loci associated with altered methylation in tumoral but not nonmalignant tissue. These tumor methylation quantitative trait loci influence chromatin structure, as well as RNA and protein abundance. One prominent tumor methylation quantitative trait locus is associated with AKT1 expression and is predictive of relapse after definitive local therapy in both discovery and validation cohorts. These data reveal intricate crosstalk between the germ line and the epigenome of primary tumors, which may help identify germline biomarkers of aggressive disease to aid patient triage and optimize the use of more invasive or expensive diagnostic assays.
Databáze: MEDLINE
Externí odkaz: